Copenhagen, 2013-03-18 12:30 CET (GLOBE NEWSWIRE) --
Report of insider transactions
Copenhagen, 18 March 2013 – Pursuant to the Danish Securities Trading Act, section 28a, Zealand Pharma A/S (“Zealand”) shall announce transactions in the company’s shares and related securities by executives and persons/companies closely related to them.
In this regard, Zealand announces the following transaction:
|Name:||David H. Solomon|
|Reason:||President and Chief Executive Officer|
|Issuer:||Zealand Pharma A/S|
|Trading date:||14 March 2013|
|Market:||NASDAQ OMX København A/S|
|Amount (number of warrants):||20,600|
|Exercise Price:||DKK 90.9323|
|Market value:||DKK 1,873,206.20|
Hereafter, David H. Solomon owns 20,600 shares and 387,150 warrants in Zealand.
# # #
For further information, please contact:
David Solomon, President and Chief Executive Officer, Tel: +45 2220 6300
Hanne Leth Hillman, Vice President and Head of IR & Corporate Communication
Tel: +45 5060 3689, email: email@example.com
Zealand Pharma A/S (“Zealand”) (NASDAQ OMX Copenhagen: ZEAL) is a biotechnology company based in Copenhagen, Denmark. Zealand specializes in the discovery, optimization and development of novel peptide drugs and has a broad and mature pipeline of drug candidates identified through its own drug discovery activities. The company’s focus lies in the field of diabetes/metabolic diseases, and its lead drug invention is lixisenatide, a once-daily GLP-1 agonist, which is licensed to Sanofi for the treatment of Type 2 diabetes. Lixisenatide is approved in Europe (February 2013) under the name of Lyxumia®, and under regulatory review in a large number of other countries globally, including in the US (NDA filed in Dec 2012) and Japan (NDA filed in June 2013).
Zealand has a partnering strategy for the development and commercialization of its products and in addition to the collaboration with Sanofi in Type 2 diabetes, the company has partnerships with Boehringer Ingelheim in diabetes/obesity, Helsinn Healthcare in chemotherapy induced diarrhea and AbbVie in acute kidney injury. For further information: www.zealandpharma.com